Search Results
Jun 11, 2026, 09:00 ET WeNatal Launches Iron+ for Targeted Iron Support Across Changing Nutritional Needs
formulated with these common challenges in mind.Each capsule contains 18 mg of Ferrochel® iron bisglycinate, a chelated form selected for its digestive tolerability and supported by clinical research, paired with 100 mg of Pureway-C® liposomal vitamin C to support iron absorption. The formula contains
More news about: WeNatal
Jun 11, 2026, 08:00 ET Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
dose of 80 mg QD (n=62), Grade ≥3 TEAEs were reported in 15/62 (24%) patients, with thrombocytopenia (6%) being the only Grade ≥3 TEAE reported in >5% of patients.Key Outcomes from the End-of-Phase 1 Meeting with the FDA80 mg QD selected
More news about: Enliven Therapeutics, Inc.
Jun 11, 2026, 08:00 ET Setria® Glutathione Earns First Registered Finished Product in Chile Through SEREMI de Salud
The Nutrapharm product contains 500mg of Setria® GlutathioneSetria, a patented, fermentation-derived form of reduced L-glutathione, is established in finished supplement products across
More news about: Kyowa Hakko U.S.A
Jun 11, 2026, 03:05 ET ZINZINO AB (PUBL.): Zinzino launches Collagen Boozt Flex as beauty-from-within enters daily routines
collagen peptides sourced from wild-caught Arctic fish from Norwegian waters, giving the formula a clear Nordic provenance. It also contains 120 mg of hyaluronic acid, vitamin C from acerola cherry, biotin, zinc, rice bran ceramides and the amino acids L-arginine and glycine.A distinguishing
More news about: Zinzino
Jun 11, 2026, 02:20 ET CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
Chemotherapy, ADCs, or Bispecifics)Overall ORR in the 30 mg/kg cohort: 24% (squamous 25%, non-squamous 23.1%, consistent benefit); DCR 60%;In second-line NSCLC (30 mg/kg, post IO + chemotherapy): ORR improved to 30.8%, DCR 84.6%.In such post-PD-(L)1
More news about: CStone Pharmaceuticals
Jun 11, 2026, 02:03 ET IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
IMAAVY and discuss any questions you have with your doctor.Dosage Form and Strengths: IMAAVY is supplied as a 300 mg/1.62 mL and a 1,200 mg/6.5 mL (185 mg/mL) single-dose vial per carton for intravenous injection.ABOUT JOHNSON & JOHNSONAt Johnson & Johnson,
More news about: Johnson & Johnson
Jun 10, 2026, 22:56 ET Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
proof-of-concept study (NCT06745583) is an ongoing, open-label trial in participants with mild-to-severe Alzheimer's disease. Participants receive enrupatinib 448.2 mg orally twice daily for 28 days, with TSPO-PET as the primary pharmacodynamic endpoint and cognitive and functional assessments as exploratory endpoints.
More news about: Elixiron Immunotherapeutics
Jun 10, 2026, 15:18 ET CDA designates 8 winning projects in its 19th annual North American Copper in Architecture Awards
Fraser Hall Chemistry Undergraduate Teaching Lab (Minneapolis, MN) | Owner: University of Minnesota (Minneapolis, Minnesota) | Sheet Metal Contractor: MG McGrath, Inc. (Maplewood, MN) | Lead Design Architect: VJAA Architects (Minneapolis, MN) | Executive Architect: BWBR Architects, Inc. (St. Paul, MN)
More news about: Copper Development Association
Jun 10, 2026, 14:24 ET Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and import authorization from the UK Home Office
More news about: Optimi Health Corp
Jun 10, 2026, 10:00 ET Hall des Lumières Unveils Renaissance: Da Vinci, Raphael, Michelangelo, A Spectacular Immersive Journey Through The Italian Renaissance
https://renaissance.halldeslumieres.com/?utm_source=google&utm_medium=sc_brand&utm_campaign=634631_nyc&utm_content=810565571423&utm_term=hall%20des%20lumieres%20renaissance_p&gad_source=1&gad_campaignid=23880209001&gbraid=0AAAAADGO9U9L_weyFytDPu3mG3D4kuML3&gcl
More news about: Hall des Lumières
Jun 10, 2026, 09:30 ET Zepbound® (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.Learn moreZepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979)
More news about: Eli Lilly and Company
Jun 10, 2026, 09:19 ET 퓨처수티컬즈 Caffinity™, 에너지와 운동 능력, 대사 기능에 임상적으로 유의미한 효과 입증
이중맹검, 위약 대조 방식으로 진행된 이번 연구에서 Caffinity 286mg(카페인 200mg 및 커피 과실 유래 폴리페놀 함유)을 섭취한 훈련된 사이클 선수들은 위약군 대비 시간기록 경기(time trial) 수행능력이 유의하게 향상됐으며, 총 운동 수행량이 평균 약 5% 증가한 것으로 나타났다(P < 0.05). 참가자들은 또한 최대 이하의 일정 강도
More news about: FutureCeuticals, Inc.
Jun 10, 2026, 09:13 ET Un estudio muestra beneficios clínicos gracias a Caffinity™ de FutureCeuticals
En el estudio doble ciego controlado con placebo, una dosis de 286 mg de Caffinity (que proporciona 200 mg de cafeína junto con polifenoles del fruto del café) mejoró significativamente el rendimiento en la contrarreloj en ciclistas entrenados,
More news about: FutureCeuticals, Inc.
Jun 10, 2026, 08:48 ET Un estudio publicado muestra los beneficios metabólicos, energéticos y de rendimiento clínicamente significativos de Caffinity™ de FutureCeuticals
En el estudio doble ciego, controlado con placebo, una dosis de 286 mg de Caffinity (que proporciona 200 mg de cafeína junto con polifenoles de la fruta del café) mejoró significativamente el rendimiento de la contrarreloj en ciclistas entrenados,
More news about: FutureCeuticals, Inc.
Jun 10, 2026, 08:41 ET Estudo publicado mostra energia, desempenho e benefícios metabólicos clinicamente significativos do Caffinity™ da FutureCeuticals
No estudo duplo-cego, controlado por placebo, uma dose de 286 mg de Caffinity (fornecendo 200 mg de cafeína juntamente com polifenóis de frutas de café) melhorou significativamente o desempenho de contra-relógio em ciclistas treinados,
More news about: FutureCeuticals, Inc.
Jun 10, 2026, 08:32 ET CocoaVia™ receives Clean Label Project™ Purity Award
following CocoaVia™ products received The Purity Award:CocoaVia™ 500mg Cocoa Flavanols CapsulesCocoaVia™ 500mg Cocoa Flavanols PowderCocoaVia™ 500mg Cocoa Flavanols Single ServingCocoaVia™ 750mg Ultra Cocoa Flavanols Capsules"We're honored that CocoaVia™ has
More news about: CocoaVia
Jun 10, 2026, 08:32 ET Veröffentlichte Studie belegt klinisch signifikante Vorteile von FutureCeuticals' Caffinity™ in Bezug auf Energie, Leistungsfähigkeit und Stoffwechsel
In der doppelblinden, placebokontrollierten Studie verbesserte eine Dosis von 286 mg Caffinity (die 200 mg Koffein sowie Polyphenole aus Kaffeekirschen lieferte) die Zeitfahrleistung bei trainierten Radfahrern signifikant und führte im Vergleich
More news about: FutureCeuticals, Inc.
Jun 10, 2026, 08:29 ET Une étude publiée démontre les bienfaits cliniquement significatifs de Caffinity™ de FutureCeuticals en matière d'énergie, de performances et de métabolisme
Dans le cadre d'une étude en double aveugle contrôlée par placebo, une dose de 286 mg de Caffinity (apportant 200 mg de caféine ainsi que des polyphénols de fruits de caféier) a considérablement amélioré les performances lors d'un contre-la-montre chez
More news about: FutureCeuticals, Inc.
Jun 10, 2026, 08:00 ET Published Study Shows Clinically Significant Energy, Performance, and Metabolic Benefits of FutureCeuticals' Caffinity™
In the double-blind, placebo-controlled study, a 286mg dose of Caffinity (providing 200mg of caffeine along with coffee fruit polyphenols) significantly improved time trial performance in trained cyclists, yielding a nearly
More news about: FutureCeuticals, Inc.
Jun 10, 2026, 08:00 ET Published Study Shows Clinically Significant Energy, Performance, and Metabolic Benefits of FutureCeuticals' Caffinity™
In the double-blind, placebo-controlled study, a 286mg dose of Caffinity (providing 200mg of caffeine along with coffee fruit polyphenols) significantly improved time trial performance in trained cyclists, yielding a nearly
More news about: FutureCeuticals, Inc.
Jun 09, 2026, 18:18 ET FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
received open-label EBGLYSS 250 mg, Q8W or Q4W, regardless of their previous treatment in ADjoin (Q2W or Q4W dose) or response at extension baseline. The approved maintenance dose of EBGLYSS is 250 mg every four weeks or 250 mg every eight weeks, after taking EBGLYSS 250 mg every two weeks for 16 weeks
More news about: Eli Lilly and Company
Jun 09, 2026, 08:02 ET ALLSPRING GLOBAL INVESTMENTS EXPANDS GLOBAL FIXED INCOME RESEARCH TEAM
be relied upon and may be subject to change without notice.© 2026 Allspring Global Investments Holdings, LLC. All rights reserved. ALL-06012026-mg7nvd8y
More news about: Allspring Global Investments
Jun 09, 2026, 05:13 ET Whole-Body Spatial Intelligence Beyond Weight-loss: nference Advances Cardiometabolism Moat for Precision Peptide Medicines and Healthy Longevity
microdosing studies," the MAIA team analyzed real-world outcomes among patients who remained on initiation-dose semaglutide (0.25 mg) or initiation-dose tirzepatide (2.5 mg) for prolonged periods14. Despite only modest weight change, sustained initiation-dose semaglutide was associated with
More news about: nference
Jun 09, 2026, 02:00 ET SEL Develops High-energy-density Lithium-ion Rechargeable Battery Having Fire Resistance, Using Novel Cathode Material LCNO (TM) (Ni-doped LCO)
to deterioration in charge-discharge cycles.SEL's newly developed LCNO (TM) involves not only doping Ni into LCO but also adding Mg. Consequently, Ni and Mg occupy Li sites in LCO with a layered rock-salt structure, thereby supporting the CoO2 layers (layered structure). It has been confirmed
More news about: Semiconductor Energy Laboratory Co., Ltd.
Jun 08, 2026, 16:15 ET Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results
randomized, placebo-controlled study included 310 adults who received 1 of 5 target doses (5 mg without titration, 15 mg without titration, 50 mg every four week titration, 75 mg once weekly titration, and 75 mg every second week titration) of elecoglipron or placebo. The primary endpoint of weight loss
More news about: American Diabetes Association